Published in J Oncol on September 06, 2009
Potential role of coregistered photoacoustic and ultrasound imaging in ovarian cancer detection and characterization. Transl Oncol (2011) 1.41
Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res (2012) 1.30
Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev (2012) 1.17
Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications. Cell Cycle (2012) 1.16
Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res (2013) 1.09
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest (2014) 1.05
Emerging roles of claudins in human cancer. Int J Mol Sci (2013) 1.05
Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protoc (2012) 1.03
The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells. PLoS One (2013) 1.02
Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J Ovarian Res (2012) 1.02
A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Oncotarget (2015) 1.00
Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol (2010) 0.99
TGF-β isoforms induce EMT independent migration of ovarian cancer cells. Cancer Cell Int (2014) 0.98
Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis (2013) 0.97
Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Mol Med (2013) 0.97
Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. Endocrinology (2012) 0.95
The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Med Rep (2011) 0.94
Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene (2014) 0.94
Increased expression of PITX2 transcription factor contributes to ovarian cancer progression. PLoS One (2012) 0.94
Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer. Br J Cancer (2013) 0.93
Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One (2013) 0.93
Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer (2013) 0.93
Ovarian cancer stem cells: a new target for cancer therapy. Biomed Res Int (2013) 0.92
Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis. PLoS One (2013) 0.92
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One (2012) 0.91
Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms. Front Oncol (2013) 0.91
Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells. PLoS One (2012) 0.90
Transformation of epithelial ovarian cancer stemlike cells into mesenchymal lineage via EMT results in cellular heterogeneity and supports tumor engraftment. Mol Med (2012) 0.89
Induction of ovarian cancer and DNA adducts by Dibenzo[a,l]pyrene in the mouse. Chem Res Toxicol (2012) 0.89
LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Gynecol Oncol (2013) 0.88
Identification of quiescent, stem-like cells in the distal female reproductive tract. PLoS One (2012) 0.87
Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer. PLoS One (2011) 0.87
Epithelial ovarian cancer and recreational physical activity: A review of the epidemiological literature and implications for exercise prescription. Gynecol Oncol (2015) 0.87
The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reprod Biol Endocrinol (2014) 0.86
FOXO1/3 and PTEN Depletion in Granulosa Cells Promotes Ovarian Granulosa Cell Tumor Development. Mol Endocrinol (2015) 0.86
Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev (2014) 0.83
PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis (2012) 0.83
Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study. PLoS One (2015) 0.83
DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Mol Cancer Res (2016) 0.81
Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases. Mol Endocrinol (2013) 0.80
Mitochondrial Superoxide Dismutase Has a Protumorigenic Role in Ovarian Clear Cell Carcinoma. Cancer Res (2015) 0.79
Assessment of ovarian cancer spheroid attachment and invasion of mesothelial cells in real time. J Vis Exp (2014) 0.79
Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Rep (2017) 0.78
The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status. Gynecol Oncol (2016) 0.78
Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer. PLoS One (2015) 0.78
VAV3 Overexpressed in Cancer Stem Cells Is a Poor Prognostic Indicator in Ovarian Cancer Patients. Stem Cells Dev (2015) 0.77
Ovarian cancer and DNA repair: DNA ligase IV as a potential key. World J Clin Oncol (2013) 0.76
Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight (2016) 0.76
Trefoil factor 1 elevates the malignant phenotype of mucinous ovarian cancer cell through Wnt/β-catenin signaling. Int J Clin Exp Pathol (2015) 0.76
Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene (2017) 0.76
Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface. Oncotarget (2016) 0.75
Overexpression of S100A14 in human serous ovarian carcinoma. Oncol Lett (2015) 0.75
Importance of spondin 1 and cellular retinoic acid binding protein 1 in the clinical diagnosis of ovarian cancer. Int J Clin Exp Pathol (2013) 0.75
Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. Gynecol Oncol (2013) 0.75
MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer. Sci Rep (2016) 0.75
Oncogenic role of mortalin contributes to ovarian tumorigenesis by activating the MAPK-ERK pathway. J Cell Mol Med (2016) 0.75
Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol (2016) 0.75
CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. J Exp Med (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol (1999) 16.81
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Cancer of the ovary. N Engl J Med (2004) 11.21
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 6.20
Screening for ovarian cancer: a pilot randomised controlled trial. Lancet (1999) 5.81
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol (2007) 5.68
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet (2000) 5.33
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12
Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol (2002) 5.07
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature (2000) 4.38
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res (2003) 4.13
The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod (1989) 4.13
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol (2007) 4.06
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94
The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol (2000) 3.86
Breast and ovarian cancer. N Engl J Med (2003) 3.84
The cell of origin of ovarian epithelial tumours. Lancet Oncol (2008) 3.74
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol (2002) 3.63
Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol (1996) 3.63
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature (2003) 3.61
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J (2006) 3.57
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 3.50
Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer (2000) 3.46
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res (2005) 3.41
New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 3.26
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol (2005) 3.26
Ovarian carcinoma diagnosis. Cancer (2000) 3.12
The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell (2001) 3.08
Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res (2003) 3.04
Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell (2007) 3.02
The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol (2004) 2.95
Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol (1983) 2.90
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res (2005) 2.72
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (1995) 2.64
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol (2008) 2.60
Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat (2008) 2.59
Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol (2003) 2.58
Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res (2003) 2.58
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer (2009) 2.48
CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol (2006) 2.47
HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol (1999) 2.34
Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA (1993) 2.28
Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol (2002) 2.18
Epidemiology of ovarian cancer. Methods Mol Biol (2009) 2.18
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res (1998) 2.07
Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer (1988) 2.02
The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol (1999) 2.00
Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ (1993) 1.98
p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A (1993) 1.93
Pathology and classification of ovarian tumors. Cancer (2003) 1.90
Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol (2009) 1.90
Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol (2009) 1.87
Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest (1994) 1.78
Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol (2001) 1.72
Ovarian cancer: can we make the clinical diagnosis earlier? Cancer (2005) 1.63
Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer (2007) 1.61
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol (1996) 1.54
Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol (2001) 1.52
Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol (2002) 1.49
Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol (2003) 1.47
Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer (2000) 1.46
Early detection of ovarian cancer: promise and reality. Cancer Treat Res (2002) 1.45
p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol (1999) 1.45
Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood) (2004) 1.40
Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol (2000) 1.35
Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int J Gynecol Cancer (2002) 1.35
Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG (2008) 1.33
Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. Eur J Cell Biol (1985) 1.33
Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol (1999) 1.30
The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.28
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
Prevalence of endometriosis in ovarian cancer. Gynecol Obstet Invest (2000) 1.26
Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol (2008) 1.25
Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol (2004) 1.22
CA 125 in benign gynecological conditions. Int J Biol Markers (1999) 1.18
Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol (2002) 1.18
Induction of a differentiated ciliated cell phenotype in primary cultures of Fallopian tube epithelium. Hum Reprod (1998) 1.17
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol (1996) 1.16
Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res (2007) 1.13
Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pract Oncol (2006) 1.12
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell (2003) 4.97
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 3.26
The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol (2007) 3.02
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A (2011) 2.71
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol (2008) 2.42
The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci U S A (2004) 2.41
BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell (2002) 2.24
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res (2007) 2.12
The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecol Oncol (2011) 2.04
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol (2011) 1.87
A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol (2011) 1.64
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol (2010) 1.57
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med (2012) 1.42
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia (2010) 1.36
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One (2012) 1.31
High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One (2011) 1.28
Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications. Am J Surg Pathol (2007) 1.25
STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) (2011) 1.23
Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res (2008) 1.23
Further evidence for BRCA1 communication with the inactive X chromosome. Cell (2007) 1.15
Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res (2013) 1.09
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res (2008) 1.09
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest (2014) 1.05
Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protoc (2012) 1.03
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A (2014) 0.99
Ex vivo culture of primary human fallopian tube epithelial cells. J Vis Exp (2011) 0.97
A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res (2008) 0.97
The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Med Rep (2011) 0.94
Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol (2011) 0.94
Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms. Front Oncol (2013) 0.91
HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci (2013) 0.90
HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci (2013) 0.85
Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity. Am J Surg Pathol (2013) 0.85
Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology (2009) 0.85
Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. Mol Oncol (2012) 0.85
Association of BRCA1 with the inactive X chromosome and XIST RNA. Philos Trans R Soc Lond B Biol Sci (2004) 0.83
Does the fimbria have an embryologic origin distinct from that of the rest of the fallopian tube? Fertil Steril (2008) 0.82
Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma. Int J Gynecol Pathol (2008) 0.81
The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC. PLoS One (2012) 0.80
GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract. Am J Surg Pathol (2015) 0.76
Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 0.75
Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol (2016) 0.75
There is a need for routine peritoneal cytology at RRSO. Gynecol Oncol (2012) 0.75
Highlights from the 2014 American Association for Cancer Research Annual Meeting. Gynecol Oncol (2014) 0.75